Clinical trials: Tace
Hepatocellular Carcinoma, Neuroendocrine Tumors
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
The goal of this clinical trial is to compare CT scan of the coverage of tumors treated with TACE using End Hole catheters to those treated with the TriNav catheter that alters tissue pressure.
- Trial name
- Trinav (NCT06204159)
- Testing
- TACE Catheters
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Hepatocellular Carcinoma (HCC), Downstaging
Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC Downstaging
The goal of this observational study is to learn about the long-term treatment outcomes for patients with initially unresectable hepatocellular carcinoma (HCC) who achieve successful downstaging with the combination therapy of…
- Conditions
- Hepatocellular Carcinoma (HCC), Downstaging, Liver Resection, Lenvatinib
- Trial name
- NCT07581769
- Testing
- Liver resection, TACE plus Lenvatinib and PD1 inhibiter
- Where
- 2 sites in China
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
- Trial name
- NCT03192644
- Testing
- TAI, TACE, epidoxorubicin and cisplatin and lipiodol
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Liver Failure
Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma
Objective: To evaluate the efficacy of preoperative liver stiffness measurement(LSM) by FibroScan in predicting the progress of liver fibrosis and prognosis after transcatheter arterial chemoembolization (TACE) in hepatocellular…
- Trial name
- NCT03285867
- Testing
- TACE
- Volunteers
- 200 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatitis B Virus, Hepatocellular Carcinoma
TACE and Adefovir Compared With Transarterial Chemoembolization (TACE) Alone for Hepatitis B Virus (HBV)-Related Unresectable Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies in China, and approximately 90% of the patients with HCC are also infected with hepatitis B virus (HBV).
- Trial name
- TACE (NCT00960518)
- Testing
- adefovir, TACE
- Where
- 2 sites in China
- Volunteers
- 216 people
- Sponsor
- Tongji University
HCC - Hepatocellular Carcinoma, SBRT
Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer
The goal of this clinical trial is to evaluate whether sequential transarterial chemoembolization (TACE) followed by stereotactic body radiotherapy (SBRT) combined with targeted immunotherapy is effective and safe for patients…
- Conditions
- HCC - Hepatocellular Carcinoma, SBRT, TACE, Immunotherapy
- Trial name
- NCT07230080
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
- Trial name
- NCT07691762
- Testing
- SHR-8068 + Adebrelimab + Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 690 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Liver Metastasis Colon Cancer
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
Transarterial chemoembolization (TACE) is an effective, minimally invasive therapy that is widely used for unresectable colorectal cancer liver metastases (CRC-LM) treatment.
- Trial name
- EMBOBEVA (NCT03732235)
- Testing
- TACE+ systemic Bevacizumab, FOLFIRI+Bevacizumab, TACE
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Giammaria Fiorentini
Unresectable Hepatocellular Carcinoma
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC
Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients.
- Trial name
- NCT05582278
- Testing
- D-TACE, HAIC, Lenvatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wen Li
Hepatic Cell Carcinoma
Effectiveness of Drug Eluting TACE in Primary HCC
the aim of this work to compare effectiveness of drug-eluting bead trans-arterial chemo-embolization and conventional trans-arterial chemo-embolization of hepatic cell carcinoma in the aspect of (Tumor response via m-RECIST…
- Trial name
- NCT04048317
- Testing
- HepaSphere Microspheres/Doxorubicin Hydrochloride, Lipiodol
- Volunteers
- 75 people
- Sponsor
- Assiut University
Liver Neoplasms
Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
Rationale: This study will compare head to head in patients with hepatocellular carcinoma (HCC) ineligible for surgery or radiofrequency ablation, the standard treatment arm, transarterial chemoembolization with drug-eluting…
- Trial name
- TRENDY (NCT02470533)
- Testing
- Radiation therapy, chemoembolization
- Where
- 11 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center